On May 8th, the top 50 pharmaceutical companies in the world, the UCB China headquarters — UCB) Huang Wenjie, Vice President of the Enterprise and Government Affairs of Youbi Trading (Shanghai) Co., Ltd., Feng Hongji, head of public affairs, and Peng Cheng He went to Shenzhen Cell Valley for investigation; Zhong Hai, deputy director of Shenzhen Science and Technology Innovation Bureau, Wang Shaowen, deputy director of the Social Development Science and Technology Division, Yang Tao, member of the Standing Committee of the Pingshan District Committee and Deputy District Chief, Liu Yingjie, Director of the Pingshan District Science and Technology Innovation Bureau, and Liao Wen, deputy director, accompanied the investigation. Essence Shi Yuanyuan, chairman of Shenzhen Cell Valley, Wang Jianxun, chief scientist, Tang Xiaomeng, deputy general manager, Wei Zheng, assistant chairman, Zhao Lijun, director of the R & D department, and Luan Zhishi, director of the comprehensive office, and discussed and exchanged. Under the leadership of the team of the team, the team and the team visited the smart exhibition hall and digital intelligent monitoring screen under the leadership of Shi Yuanyuan. They initially learned about the development process, strategic layout, team strength, and the use of their unique core technology -reverse virus carrier technology technology (PACK-SS and other systems) The high-production capacity and low-cost advantages of CAR-T and CAR-NK cell products prepared by CACK-SS). At the symposium, Chairman Shi Yuanyuan said that he sincerely thanked the city and district leaders for their support and trust in cell valleys. As the only company in Pingshan District, the cell valley was honored by the Chinese headquarters in Pingshan District. Subsequently, the current status of the cell therapy industry, the industrial layout of Shenzhen Cell Valley in cells and gene therapy, and the progress of clinical application of products and scientific research. Shi Yuanyuan said that the product pipeline independently developed by Shenzhen Cell Valley has made breakthrough progress from R & D to production to clinical clinical. The clinical application of cell products has matured, which will bring in -depth changes to the field of cells and gene therapy; not genetic Modified immune cell products, especially the preparation level of the nk cell product of peripheral blood sources, is much higher than the same type of album transplantation standards identified by the FDA. The field of field play has made important contributions to precise health management.

Ugly Bi Bi President Huang Wenjie highly recognizes the core strength of the cell valley team and the company's technological development prospects. Ugami will use the innovative concept of reinforcement, link, empowerment, and win -win in China to create an open innovative ecological ecology in China Focusing on the needs of patients, I hope to take this exchange as an opportunity, strengthen cooperation, share resources, create new ideas, and jointly use agile and autonomous innovation capabilities to provide new possibilities for more disease treatment. With the support of good innovation environment and policy, promote the high -quality development of the biomedical industry.